Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.
The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Lepu Scientech Medical Technology (Shanghai) Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 21.28%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) Earnings Yield % Explanation
If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.
If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.
Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.
Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.
Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.
Lepu Scientech Medical Technology (Shanghai) Co Earnings Yield % Related Terms
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) has a Earnings Yield % of 6.21% as of Aug. 20, 2026. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors.
Is Lepu Scientech Medical Technology (Shanghai) Co's Earnings Yield % too high?
Lepu Scientech Medical Technology (Shanghai) Co's current Earnings Yield % is 6.21%. Overall, Lepu Scientech Medical Technology (Shanghai) Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lepu Scientech Medical Technology (Shanghai) Co's Earnings Yield % compare to ABT and SYK?
Lepu Scientech Medical Technology (Shanghai) Co's Earnings Yield % of 6.21% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield % for a Medical Devices & Instruments company?
A good Earnings Yield % depends on the Medical Devices & Instruments industry context. However, Earnings Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield % mean?
A high Earnings Yield % can signal that a stock is expensive relative to its fundamentals. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on Lepu Scientech Medical Technology (Shanghai) Co and its competitors. Lepu Scientech Medical Technology (Shanghai) Co's current Earnings Yield % is 6.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Scientech Medical Technology (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$44.29, compared to a current price of HK$12.18 — trading 72.5% below its estimated fair value. The current Earnings Yield % is 6.21%. Lepu Scientech Medical Technology (Shanghai) Co's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield % calculated?
Earnings Yield % is calculated from a company's financial statements. For Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291), the current Earnings Yield % is 6.21% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Scientech Medical Technology (Shanghai) Co (HKSE:02291) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Scientech Medical Technology (Shanghai) Co stock appears to be undervalued.
The current stock price of HK$12.18 is trading 72.5% below its estimated GF Value™ of HK$44.29.
GuruFocus considers Lepu Scientech Medical Technology (Shanghai) Co to be Significantly Undervalued.
Key valuation signals for HKSE:02291:
Earnings Yield %: 6.21%
GF Value™: HK$44.29 vs. price of HK$12.18 (72.5% below fair value)
No single metric tells the full story. See the HKSE:02291 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Scientech Medical Technology (Shanghai) Co Ltd is focused on the research and development, manufacture, and commercialization of heart disease interventional medical devices. The reporting segments of the Group are as follows: The Occluder business segment and The heart valve business segment. The company generates majority of its revenue from the Occluder segment which is engaged in the research and development, manufacturing and sales of interventional treatment series occluders for the defective congenital heart disease.
76GF Score
Get the complete analysis for HKSE:02291
Earnings Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02291 has been successfully added to your 
